NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer SEATTLE , April 27, 2011 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Carlos V. Paya , MD, PhD, will join IDC as Chief Executive Officer and Board Director effective May 2,
View HTML
Toggle Summary Immune Design Grants Adjuvant License to MedImmune
Immune Design Grants Adjuvant License to MedImmune SEATTLE , Oct. 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has entered into a license and development
View HTML
Toggle Summary Immune Design Corp. Raises $32 Million in Series B Financing
Immune Design Corp. Raises $32 Million in Series B Financing SEATTLE , July 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32
View HTML
Toggle Summary Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology
View HTML